MORF Jul 2024 30.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
At close: 02:08PM EDT
Loading interactive chart...
- GuruFocus.com
Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review
Insights into Financial Performance and Strategic Developments
- GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
- Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Appointed Dr. Simon Cooper as Chief Medical Officer- -Anticipate dosing first patient in GARNET Phase 2 study of MORF-057 in patients with moderate-to-severe Crohn’s disease in second quarter- -Ended first quarter with $658.8 million in cash, cash equivalents, and marketable securities; cash runway into second half of 2027- WALTHAM, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasda
- Zacks
What Makes Morphic (MORF) a New Buy Stock
Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
© 2024 Yahoo. All rights reserved.